CMC Biologics and RuiYi link on MAb; Deal for Cynviloq rights in EU

Denmark and USA-based contract manufacturers CMC Biologics has entered into an agreement with China’s RuiYi to develop a cell line for RYI-008, a novel anti-inteleukin-6 monoclonal antibody. CMC Biologics' proprietary CHEF1 high-productivity expression plasmid will be utilized for the cell line development to optimize cell growth, and consistent, high-level protein expression in a rapid time frame. Specific terms of the agreement were not disclosed.

"We are pleased with the opportunity to build a long-term relationship with RuiYi on the development of RYI-008. RYI-008 is an antibody with unprecedented potency and remarkable half-life, creating a significant opportunity to be a best in class product in the rapidly evolving field of IL-6 biology." said Mark Sawicki, global vice president business development of CMC Biologics, adding: "This agreement underscores our strategic focus on biologics development in emerging markets."

Sorrento Therapeutic and IGDRASOL acquire distribution rights to Cynviloq in EU